Evaluating Tumor-Infiltrating Lymphocytes in Breast Cancer Using Preoperative MRI-Based Radiomics

被引:29
|
作者
Bian, Tiantian [1 ]
Wu, Zengjie [2 ]
Lin, Qing [1 ]
Mao, Yan [1 ]
Wang, Haibo [1 ]
Chen, Jingjing [1 ]
Chen, Qianqian [3 ]
Fu, Guangming [4 ]
Cui, Chunxiao [1 ]
Su, Xiaohui [1 ]
机构
[1] Qingdao Univ, Affiliated Hosp, Breast Dis Ctr, Qingdao, Peoples R China
[2] Qingdao Univ, Affiliated Hosp, Dept Radiol, Qingdao, Peoples R China
[3] GE Healthcare, Precis Hlth Inst, Shanghai, Peoples R China
[4] Qingdao Univ, Affiliated Hosp, Dept Pathol, Qingdao, Peoples R China
关键词
radiomics signature; MRI; breast cancer; tumor-infiltrating lymphocytes; PROGNOSTIC VALUE; CHEMOTHERAPY; LEVEL;
D O I
10.1002/jmri.27910
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background Evaluating tumor-infiltrating lymphocytes (TILs) in patients with breast cancer using radiomics has been rarely explored. Purpose To establish a radiomics nomogram based on dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for preoperatively evaluating TIL level. Study Type Retrospective. Population A total of 154 patients with breast cancer were divided into a training cohort (N = 87) and a test cohort (N = 67), who were further divided into low TIL (<50%) and high TIL (>= 50%) subgroups according to the histopathological results. Field Strength/Sequence 3.0 T; axial T2-weighted imaging (fast spin echo), diffusion-weighted imaging (spin echo-echo planar imaging), and the volume imaging for breast assessment DCE sequence (gradient recalled echo). Assessment A radiomics signature was developed from the training dataset and independent risk factors were selected by multivariate logistic regression to build a clinical model. A nomogram model was built by combining radiomics score and risk factors. The performance of the nomogram was assessed using calibration curves and decision curves. The area under the receiver operating characteristic (ROC) curve, accuracy, sensitivity, and specificity were calculated. Statistical Tests The least absolute shrinkage and selection operator, univariate and multivariate logistic regression analysis, t-tests and chi-squared tests or Fisher's exact test, Hosmer-Lemeshow test, ROC analysis, and decision curve analysis were conducted. P < 0.05 was considered statistically significant. Results The radiomics signature and nomogram model exhibited better calibration and validation performance in the training (radiomics: area under the curve [AUC] 0.86; nomogram: AUC 0.88) and test (radiomics: AUC 0.83; nomogram: AUC 0.84) datasets compared with clinical model (training: AUC 0.76; test: AUC 0.72). The decision curve demonstrated that the nomogram model exhibited better performance than the clinical model, with a threshold probability between 0.15 and 0.9. Data Conclusion The nomogram model based on preoperative MRI exhibited an excellent ability for the noninvasive evaluation of TILs in breast cancer. Level of Evidence 4 Technical Efficacy Stage 2
引用
收藏
页码:772 / 784
页数:13
相关论文
共 50 条
  • [21] Tumor-infiltrating lymphocytes/macrophages and clinical outcome in breast cancer
    Kim, Y-S.
    Kim, J-S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [22] Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in Breast Cancer
    Kwa M.
    Adams S.
    Current Breast Cancer Reports, 2016, 8 (1) : 1 - 13
  • [23] Diagnostic and Therapeutic Implications of Tumor-Infiltrating Lymphocytes in Breast Cancer
    Denkert, Carsten
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (07) : 836 - 837
  • [24] In situ cytokine production by breast cancer tumor-infiltrating lymphocytes
    Camp, BJ
    Dyhrman, ST
    Memoli, VA
    Mott, LA
    Barth, RJ
    ANNALS OF SURGICAL ONCOLOGY, 1996, 3 (02) : 176 - 184
  • [25] Significance of tumor-infiltrating lymphocytes in breast cancer with neoadjuvant chemotherapy
    Miyoshi, Y.
    Shien, T.
    Omori, M.
    Abe, Y.
    Watanabe, A.
    Hara, A.
    Mizoo, T.
    Nogami, T.
    Taira, N.
    Doihara, H.
    BREAST, 2015, 24 : S124 - S124
  • [26] Nomogram to Predict Tumor-Infiltrating Lymphocytes in Breast Cancer Patients
    Feng, Jikun
    Li, Jianxia
    Huang, Xinjian
    Yi, Jiarong
    Wu, Haoming
    Zou, Xuxiazi
    Zhong, Wenjing
    Wang, Xi
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2021, 8
  • [27] Spatial Characterization of Tumor-Infiltrating Lymphocytes and Breast Cancer Progression
    Fassler, Danielle J.
    Torre-Healy, Luke A.
    Gupta, Rajarsi
    Hamilton, Alina M.
    Kobayashi, Soma
    Van Alsten, Sarah C.
    Zhang, Yuwei
    Kurc, Tahsin
    Moffitt, Richard A.
    Troester, Melissa A.
    Hoadley, Katherine A.
    Saltz, Joel
    CANCERS, 2022, 14 (09)
  • [28] CANCER-IMMUNOTHERAPY USING TUMOR-INFILTRATING LYMPHOCYTES
    FIGLIN, RA
    SEMINARS IN HEMATOLOGY, 1992, 29 (02) : 33 - 35
  • [29] MRI-Based Radiomics for Preoperative Prediction of Lymphovascular Invasion in Patients With Invasive Breast Cancer
    Nijiati, Mayidili
    Aihaiti, Diliaremu
    Huojia, Aisikaerjiang
    Abulizi, Abudukeyoumujiang
    Mutailifu, Sailidan
    Rouzi, Nueramina
    Dai, Guozhao
    Maimaiti, Patiman
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [30] Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
    Leon-Ferre, Roberto A.
    Jonas, Sarah Flora
    Salgado, Roberto
    Loi, Sherene
    de Jong, Vincent
    Carter, Jodi M.
    Nielsen, Torsten O.
    Leung, Samuel
    Riaz, Nazia
    Chia, Stephen
    Jules-Clement, Gerome
    Curigliano, Giuseppe
    Criscitiello, Carmen
    Cockenpot, Vincent
    Lambertini, Matteo
    Suman, Vera J.
    Linderholm, Barbro
    Martens, John W. M.
    van Deurzen, Carolien H. M.
    Timmermans, A. Mieke
    Shimoi, Tatsunori
    Yazaki, Shu
    Yoshida, Masayuki
    Kim, Sung-Bae
    Lee, Hee Jin
    Dieci, Maria Vittoria
    Bataillon, Guillaume
    Vincent-Salomon, Anne
    Andre, Fabrice
    Kok, Marleen
    Linn, Sabine C.
    Goetz, Matthew P.
    Michiels, Stefan
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 331 (13): : 1135 - 1144